. 2021 Nov 5;12:753890. doi: 10.3389/fimmu.2021.753890
Copyright © 2021 Guolo, Minetto, Pesce, Ballerini, Clavio, Cea, Frello, Garibotto, Greppi, Bozzo, Miglino, Passannante, Marcolin, Tedone, Colombo, Mangerini, Bo, Ruzzenenti, Carlier, Serio, Luchetti, Dominietto, Varaldo, Candiani, Agostini, Ravetti, Del Zotto, Marcenaro and Lemoli
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Figure 3.
Cytotoxic NK cell/ul before and after ALI in all patients receiving ALI + nivolumab.